Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Toshitaka Manda"'
Autor:
Shigeru Takeshita, Toshitaka Manda, Shoji Takakura, Ikuo Kawamura, Seitaro Mutoh, Miyuki Mabuchi, Hideaki Minoura, Tadashi Yamamoto, Jiro Hirosumi, Makoto Ita, Jiro Seki
Publikováno v:
European Journal of Pharmacology. 519:182-190
Effect of 3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide (FK614), a novel nonthiazolidinedione peroxisome proliferator-activated receptor (PPAR) gamma agonist, on glucose tolerance and insulin resistance in peripher
Autor:
Naoki Sogo, Seitaro Mutoh, Toshitaka Manda, Yuka Sasakawa, Masahiko Matsuo, Tatsuya Sasakawa, Yoshinori Naoe, Takeshi Inoue
Publikováno v:
Biochemical Pharmacology. 69:603-616
In this study, we detected genes sensitive to an histone deacetylase inhibitor, FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo-[8,7,6]-tricos-16-ene-3,6,9,19,22-pentanone; FR901228, depsipe
Autor:
Masae Sawada, Akira Nagayoshi, Koji Ueshima, Hitomi Akihisa-Umeno, Tohru Ozaki, Seitaro Mutoh, Toshitaka Manda, Shoji Takakura
Publikováno v:
Life Sciences. 76:179-190
Evidence has been accumulating that triglyceride (TG)-rich lipoproteins are atherogenic. Microsomal TG transfer protein (MTP) is essential for the synthesis of both chylomicron in the intestine and very low density lipoprotein in the liver. To invest
Autor:
Jiro Hirosumi, Masayuki Tomita, Naomi Hosogai, Seitaro Mutoh, Toshitaka Manda, Kaori Hamada, Toshikazu Ogawa
Publikováno v:
European Journal of Pharmacology. 477:171-178
Our recent study suggests that there is a reciprocal mechanism to maintain cGMP content, via both a decrease in cGMP degradation (decrease in cGMP-phosphodiesterase activity) and an increase in synthesis of cGMP (increase in guanylate cyclase activit
Publikováno v:
European Journal of Pharmacology. 473:65-70
Cyclic guanosine-3',5'-monophosphate (cGMP)-mediated mechanisms play an important role in vasodilation and blood pressure regulation. We investigated basal activity of the nitric oxide (NO)-cGMP signal transduction pathway in corpus cavernosum from b
Autor:
Toshitaka Manda, Toshio Goto, Yuka Sasakawa, Masahiko Matsuo, Fusako Nishigaki, Ikuo Kawamura, Sanae Matsumoto, Susumu Tsujimoto, Masamichi Inami, Yoshinori Naoe
Publikováno v:
Cancer Letters. 181:39-45
The effects of FK317 (11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14-oxa-1,11-diazatetraacylo[7.4.1.0 2,7 .0 10,2 ]tetradeca-2,4,6-trien-9-yl acetate), a novel anti-cancer agent, and mitomycin C (MMC) on survival time of mice bearing B16BL6 mel
Autor:
Masahiko Matsuo, Hiroe Nakayama, Wataru Uchida, Koji Takeshita, Hisashi Yamakuni, Katsunori Imazumi, Toshitaka Manda, Takako Furukawa
Publikováno v:
Biologicalpharmaceutical bulletin. 37(2)
The antiemetic effect of a potent and selective neurokinin-1 (NK1) receptor antagonist, FK886 ([3,5-bis(trifluoromethyl)phenyl][(2R)-2-(3-hydroxy-4-methylbenzyl)-4-{2-[(2S)-2-(methoxymethyl)morpholin-4-yl]ethyl}piperazin-1-yl]methanone dihydrochlorid
Autor:
Susumu Tsujimoto, Sanae Matsumoto, Ikuo Kawamura, Masamichi Inami, Toshitaka Manda, Fusako Nishigaki, Yoshinori Naoe, Kyoichi Shimomura
Publikováno v:
Japanese Journal of Cancer Research : Gann
The effects of FK317 (11-acetyl-8-carbamoyloxymethyl-4-formyl-6- methoxy-14-oxa-1,11-diazatetracyclo[7.4.1.0(2, 7). 0(10, 2] tetradeca-2,4,6-trien-9-yl acetate), a novel anti-cancer agent, on murine adenocarcinoma colon26- and human lung carcinoma LX
Autor:
Ikuo Kawamura, Shoji Takagaki, Sanae Matsumoto, Fusako Nishigaki, Kyoichi Shimomura, Toshitaka Manda, Yoshinori Naoe, Masamichi Inami, Susumu Tsujimoto
Publikováno v:
Japanese Journal of Cancer Research : Gann
FK317, a novel substituted dihydrobenzoxazine, was examined for antitumor effects on multidrug‐resistant (MDR) tumor cells in vitro and in vivo. In nude mice, FK317 markedly inhibited the growth of s.c. implanted KB‐V1 vinblastine (VLB)‐resista
Autor:
Masaaki Matsuo, Yu Sudo, Toshitaka Manda, Takashi Ogino, Nobuo Seki, Fusako Nishigaki, Kiyoshi Tsuji, Masae Sawada
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:2473-2478
5-(2-Pyridylsulfonyl)-2-thiazolamine (2) was effective both in mitomycin C (MMC)-induced thrombocytopenia and in an animal model of idiopathic thrombocytopenic purpura (ITP). It also suppressed the increase of autoantibodies against platelets in the